Pfizer, IncNYSE: PFE

No material news in the last 48 hours.

Michael Burry's latest 13F disclosure included Pfizer as a new buy, drawn by the 6.66% dividend yield and roughly 9x forward P/E. Pfizer entered settlements with Dexcel Pharma, Hikma Pharmaceuticals and Cipla regarding Vyndamax patent infringement, extending the effective U.S. patent expiry to June 1, 2031. Pfizer continues to focus on oncology, where its drugs now represent roughly 27% of total revenue. The 2026 full-year guidance was reaffirmed at $2.80-$3.00 adjusted EPS and revenue of $59.5B-$62.5B. The stock trades around $25.75 with notable valuation gap vs. peers.

Michael Burry's Latest Buys Include a 6.66% Yielding Pharma Giant247wallst.comIs Pfizer a Buy, Sell, or Hold in 2026?fool.com

Pfizer announced settlement agreements with Dexcel Pharma, Hikma Pharmaceuticals, and Cipla to resolve patent infringement lawsuits related to VYNDAMAX (tafamidis), pushing effective US patent expiry to June 1, 2031. As a result, VYNDAMAX revenues are now expected to stay relatively stable from 2028 through mid-2031, removing a near-term overhang on one of Pfizer's most important post-COVID growth drugs. Separately, Pfizer and Valneva reported their Lyme disease vaccine candidate showed 73.2% efficacy in the Phase 3 VALOR trial, with regulatory submissions planned. However, shares have been pressured by reports that TrumpRx is set for a 'dramatic expansion,' raising drug-pricing risk. Risk: ongoing patent cliff, pricing/IRA pressures, and uncertain pipeline contribution beyond 2028 keep analysts cautious despite the 6.8% dividend yield.

Pfizer Reaches Three Settlement Agreements for VYNDAMAXpfizer.comPfizer and Valneva Announce Lyme Disease Vaccine Phase 3 VALOR Resultspfizer.comGoldman Sachs resets Pfizer stock forecastthestreet.com

Michael Burry's Scion disclosed a new Pfizer position, with the stock trading around $25.75 at a 6.66% dividend yield and ~9x forward P/E. PFE entered patent settlement agreements with Dexcel, Hikma, and Cipla extending the effective US patent expiry on Vyndamax to June 1, 2031, protecting a key franchise from generic entry. Q1 2026 revenue of $14.5B (up 5% YoY) beat estimates as new and acquired products offset declining Covid vaccine and Paxlovid sales, and the company reaffirmed full-year guidance of $2.80-3.00 adjusted EPS and $59.5-62.5B revenue. Oncology and weight-loss pipeline progress and 22% operational growth on new launches underpinned the print. Risk: Paxlovid/Covid vaccine revenue is expected to decline another ~$1.5B to roughly $5B, and longer-term revenue base remains in transition.

Pfizer (PFE) earnings Q1 2026cnbc.comMichael Burry's Latest Buys Include a 6.66% Yielding Pharma Giant247wallst.comPfizer Reports Strong First-Quarter Resultsbusinesswire.com

No material news in the last 48 hours.

Pfizer reported Q1 2026 revenue of $14.45B (up from $13.72B YoY) and adjusted EPS of $0.75, beating estimates. Management reaffirmed 2026 guidance: $59.5B-$62.5B revenue and $2.80-$3.00 adjusted EPS. Recently launched and acquired products grew 22% YoY operationally, offsetting expected $1.5B drop in Covid product revenue (to $5B) and a similar $1.5B headwind from loss-of-exclusivity drugs. Pipeline wins include FDA approval of VEPPANU, positive Phase 3 ELREXFIO results, and VYNDAMAX patent extension to 2031. Board declared a $0.43 Q2 dividend payable June 12. Pfizer is leveraging the $10B Metsera obesity acquisition for long-term growth. Stock trades at ~9.1x forward earnings with a 6.7% dividend yield. Risk: declining Covid revenue and patent cliffs continue to pressure top line.

Pfizer (PFE) earnings Q1 2026cnbc.comPfizer Reports Strong First-Quarter Results And Reaffirms 2026 Guidancebusinesswire.comWhat Pfizer (PFE)'s Earnings Beat, Reaffirmed Guidance and Oncology Wins Mean For Shareholderssimplywall.st

Pfizer reaffirmed its full-year 2026 outlook of $2.80-$3.00 adjusted EPS and $59.5-$62.5B revenue after Q1 revenue of $14.5B (+2% operational), with the core business excluding COVID products growing 7% operationally. The 'launched and acquired' portfolio delivered 22% operational revenue growth, anchored by Padcev (oncology), Nurtec ODT (migraine), and Abrysvo (RSV). The board declared a $0.43 Q2 dividend (350th consecutive quarterly dividend). Pipeline progress includes FDA approval of VEPPANU, positive Phase 3 results for ELREXFIO, and VYNDAMAX patent extension through 2031. Goldman Sachs reset its Pfizer forecast on May 12, with analysts framing PFE as a 'classic hold' trading near $26.58 with a consensus PT of $29.29 (~10% upside) plus a 6.7% dividend yield. Risk: loss-of-exclusivity wave for older drugs over the next few years will weigh on top line; LOE remains the dominant overhang.

Pfizer (PFE) earnings Q1 2026 - CNBCcnbc.comGoldman Sachs resets Pfizer stock forecast - TheStreetthestreet.comIs Pfizer a Buy, Sell, or Hold in 2026? - Motley Foolfool.com

Pfizer posted Q1 2026 earnings and revenue that topped estimates as recently launched and acquired products showed growth, offsetting declining Covid vaccine and Paxlovid revenue. The company reaffirmed 2026 outlook with adjusted EPS of $2.80-$3.00 and revenue of $59.5B-$62.5B. Pipeline advances include FDA approval of VEPPANU, positive Phase 3 results for ELREXFIO, and VYNDAMAX patent extension to 2031. Goldman Sachs lowered its price target while maintaining a Hold rating. Consensus among 30 analysts is Buy. Loss of exclusivity and oncology competition remain key risks.

Pfizer Q1 2026 earningscnbc.comGoldman Sachs resets Pfizer stock forecastthestreet.comPfizer Earnings Beat and Oncology Winssimplywall.st

Pfizer reported Q1 2026 EPS of $0.75 (ex-items) and revenue of $14.45B versus $13.72B a year ago, topping estimates. The company reaffirmed full-year 2026 adjusted EPS guidance of $2.80-$3.00 and revenue of $59.5B-$62.5B. Launched and acquired products grew 22% operationally, with Padcev up 39% and oncology biosimilars up 52%, helping offset an expected $1.5B decline in Covid product sales. Pfizer also extended VYNDAMAX patent protection through 2031 and is pursuing a $10B acquisition of obesity biotech Metsera. Risk: continued exclusivity losses are expected to drive another $1.5B revenue headwind in 2026. Goldman Sachs reset its Pfizer price forecast around the same period.

Pfizer (PFE) earnings Q1 2026cnbc.comPfizer Reports Strong First-Quarter Results And Reaffirms 2026 Guidancebusinesswire.comGoldman Sachs resets Pfizer stock forecastthestreet.com

Pfizer reported Q1 2026 total revenues of $14.5 billion with a 2% operational increase YoY, beating estimates as recently launched and acquired products showed growth. The company reaffirmed full-year 2026 guidance of $2.80-$3.00 adjusted EPS and $59.5-$62.5 billion revenue. Key performance drivers included 22% operational revenue growth in the launched and acquired portfolio, led by oncology drug Padcev, migraine treatment Nurtec ODT, and RSV vaccine Abrysvo, offsetting declines in Covid franchise (Comirnaty and Paxlovid). Pfizer advanced its pipeline with FDA approval of VEPPANU, positive Phase 3 results for ELREXFIO, and extended VYNDAMAX patent protection through 2031. The board declared a $0.43 Q2 dividend payable June 12, marking the 350th consecutive quarterly dividend.

Pfizer earnings Q1 2026cnbc.comPfizer Reports Strong First-Quarter Results And Reaffirms 2026 Guidancebusinesswire.comPfizer Q1 2026 Financial Resultsbiotechreality.com

Pfizer reported Q1 2026 earnings on May 5 that exceeded Wall Street expectations with $14.5 billion revenue (vs $13.84B consensus) and $0.75 adjusted EPS (vs $0.72 estimate). Revenue reflected 2% operational growth, or 7% when excluding COVID-19 product declines. The company's launched and acquired portfolio surged 22% operationally, driven by oncology drug Padcev, migraine treatment Nurtec ODT, and RSV vaccine Abrysvo. Pfizer reaffirmed full-year 2026 guidance of $2.80-3.00 EPS and $59.5-62.5B revenue. FDA approved the Pfizer-Arvinas breast cancer drug, and Elrexfio met primary trial goals in blood cancer. Board declared $0.43 Q2 dividend, the 350th consecutive quarterly payment.

Pfizer Reports Strong First-Quarter Results And Reaffirms 2026 Guidancebusinesswire.comPfizer (PFE) earnings Q1 2026cnbc.comQ1 2026 Financial Results: Robust Growth Driven by Oncology and New Launchesbiotechreality.com

Pfizer posted Q1 2026 EPS of $0.75 beating estimates of $0.72 with revenue of $14.5 billion. Company reaffirmed 2026 guidance of $59.5-$62.5 billion revenue and $2.80-$3.00 adjusted EPS. Reached settlement agreements extending VYNDAMAX patent protection to June 2031. Received FDA approval for Veppanu (with Arvinas) - first oral PROTAC and third oral SERD for breast cancer. Declared $0.43 Q2 dividend. Stock at $26.50 with 6.5% yield and P/E of 19.4. Analyst consensus: Buy with average price target of $29.29.

Yahoo Finance - PFEfinance.yahoo.comCNBC - PFEcnbc.comPfizer Newsroompfizer.com

Pfizer and Arvinas' Veppanu, a first PROTAC and third oral SERD for breast cancer, won FDA approval on May 2, 2026. Additionally, ELREXFIO (elranatamab) met primary endpoint in phase 3 MagnetisMM-5 trial for multiple myeloma. Pfizer also settled patents disputes for VYNDAMAX with three generic manufacturers, extending U.S. patent exclusivity to June 1, 2031. Guggenheim maintains Buy with $36 PT. Q1 2026 earnings beat expectations.

Pfizer Scores an FDA Approval and a Patent Win in One Weektikr.comGuggenheim Reaffirms Buy on Pfizer (PFE) Ahead of Pipeline Catalystsfinance.yahoo.comPfizer Inc. - Investor Relationsinvestors.pfizer.com